Lv11
85 积分 2020-11-01 加入
Hamilton MP, Miklos DB, Alizadeh AA. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med 2024; 391: 870–71
51分钟前
待确认
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
54分钟前
已完结
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells
8小时前
已完结
Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems
13天前
已完结
Primary testicular lymphoma
20天前
已完结
T-cell lymphoblastic lymphoma in children, adolescents and young adults
21天前
已完结
A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma-leg type
29天前
已完结
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
3个月前
已完结
High-risk MCL: recognition and treatment
3个月前
已完结
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
3个月前
已完结
皖公网安备34019202002308